This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Chonluten (20 mg Vial)
Chonluten is a short bioregulatory tripeptide (Glu-Asp-Gly) studied for its effects on bronchopulmonary tissue and inflammatory pathways in monocyte/macrophage cell models[1]. This compound is described as having limited oral stability[2].
Quick Reference
What is Chonluten?
Research overview based on the cited scientific literature.
• Goal: Support bronchopulmonary tissue function and modulate inflammatory pathways[1].
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality[3].
• Lyophilized (short-term): Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
• Lyophilized (long-term): Store at −20 °C (−4 °F) or colder; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within days to weeks and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Chonluten studied?
Chonluten (Glu-Asp-Gly) is a short bioregulatory peptide studied within the Khavinson peptide bioregulator framework targeting bronchopulmonary tissues[1]. In vitro research using monocyte/macrophage (THP-1) cell models indicates Chonluten may modulate proliferative activity and inflammatory pathways at concentrations in the nanomolar range[1]. Short peptides such as Chonluten typically exhibit poor oral bioavailability due to enzymatic degradation and limited mucosal permeability, supporting subcutaneous administration as the preferred route[2][5].
What does the research report about Chonluten?
Observations from preclinical literature.
• May support bronchopulmonary tissue function and respiratory cell regulation based on bioregulator peptide research[1].
• Cell-culture studies suggest modulation of inflammatory and proliferative pathways in monocyte/macrophage models[1].
• Short peptides in this class generally show favorable tolerability profiles in preclinical settings[5].
• Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Chonluten?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.